Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: A systematic review and meta-analysis

Prostate Cancer and Prostatic Diseases

Volumn 20, Issue 3, 2017, Pages 352-360

  Calopedos, R J S ^a   Chalasani, V ^b   Asher, R ^a   Emmett, L ^c   Woo, H H ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DKZ LU 177; DOTAGA (I-Y)FK LU 177; MONOCLONAL ANTIBODY J591; MONOCLONAL ANTIBODY J591 LU 177; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOLIGAND; UNCLASSIFIED DRUG; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; LIGAND; LUTETIUM; LUTETIUM-177; MEMBRANE ANTIGEN; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; DRUG DOSE ESCALATION; DRUG EFFICACY; HUMAN; ISOTOPE LABELING; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; MALE; META ANALYSIS;

ANTIGENS, SURFACE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; KALLIKREINS; LIGANDS; LUTETIUM; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOISOTOPES; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 85030756743     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2017.23     Document Type: Article

References (37)

1. Conford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T et al. EAU-ESTROSIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic and castration-resistant prostate cancer. Eur Urol 2017; 71: 630-642.
2. Kulkarni HR, Singh A, Schuchardt C, Niepsch K, Sayeg M, Leshch Y et al. PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: the bad berka experience 2013. J Nucl Med 2016; 57: 97S-104S.
3. Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S et al. 177Lulabeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med 2016; 57: 1006-1013.
4. Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, Navarro V et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 1998; 58: 4055-4060.
5. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumour vascular endothelium. Cancer Res 1997; 57: 3629-3634.
6. Vallabhajosula S, Nikolopoulou A, Jhanwar YS, Kaur G, Tagawa ST, Nanus DM et al. Radioimmunotherapy of metastatic prostate cancer with 177Lu-DOTA-huJ591 anti-prostate specific membrane antigen specific monoclonal antibody. Curr Radiopharm 2016; 9: 44-53.
7. Bander NH, Trabulsi EJ, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 2003; 170: 1717-1721.
8. Kularatne SA, Zhou Z, Yang J, Post CB, Low PS. Design, synthesis, and pre-clinical evaluation of prostate specific membrane antigen targeted 99mTc-radioimmaging agents. Mol Pharm 2009; 6: 790-800.
9. Zhang AX, Murelli RP, Barinka C, Michel J, Cocleaza A, Jorgensen WL et al. A remote arene-bidning site on prostate specific membrane antigen revealed by antibody-recruiting small molecules. J Am Chem Soc 2010; 132: 12711-12716.
10. Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S et al. 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA targeted theranostic concept and first proof of concept human studies. J Nucl Med 2015; 56: 1169-1176.
11. Hillier SM, Maresca KP, Femia FJ, Marquis JC, Foss CA, Nguyen N et al. Pre-clinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res 2009; 69: 6932-6940.
12. Benesova M, Schafer M, Bauder-Wust U, Afshar-Oromieh A, Kratochwil C, Mier W et al. Preclinical evaluation of tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med 2015; 56: 914-920.
13. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium labeled J591, a monoclonal antibody to prostatespecific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005; 23: 4591-4601.
14. Tagawa ST, Milowsky M, Morris M, Vallabhajosula S, Christos P, Akhtar NH et al. Phase II study of Lutetium-177-labelled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res 2013; 46: 220-231.
15. Ahmadzadehfar H, Rahbar K, Kurpig S, Bogemann M, Claesener M, Eppard E et al. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res 2015; 5: 1-8.
16. Heck MM, Retz M, D'Alessandria C, Rauscher I, Scheidhauer K, Maurer T et al. Systemic radioligand therapy with 177Lu labeled prostate specific membrane for imaging and therapy in patients with metastatic castration-resistant prostate cancer. J Urol 2016; 196: 382-391.
17. Fendler WP, Reinhardt S, Ilhan H, Delker A, Boning G, Gildehaus FJ et al. Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. Oncotarget 2016; 8: 3581-3590.
18. Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Essler M et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med 2017; 58: 85-90.
19. Tagawa ST, Batra J, Vallabhajosula S, Jhanwar Y, Christos PJ, Emmerich L et al. Final results of 2-dose fractionation of 177Lu-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC). Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO. J Clin Oncol 2016; 34 (abstract 5022).
20. Rathore H, Shah H, Aland P, Chaudhuri P, Bharadwaj T, Kale C et al. Assessment of response, clinical evaluation and toxicity of radioligand therapy (RLT) with 177- Lutetium-DKFZ-617-labeled prostate specific membrane antigen (177-Lu-DKFZ-617-PSMA) for metastatic castrate resistant prostate cancer (mCRPC): an initial experience in Jaslok. Conference: 29th Annual Congress of the European Association of Nuclear Medicine, EANM 2016, Spain. Eur J Nucl Med Mol Imaging 2016; 43: S414.
21. Yadav MP, Ballal S, Tripathi M, Damle NA, Sahoo RK, Seth A et al. 177Lu-DKFZPSMA- 617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment. Eur J Nucl Med Mol Imaging 2017; 44: 81-91.
22. Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 2011; 65: 1180-1192.
23. Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, Frame JN et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care, Ontario clinical practice guideline. J Clin Oncol 2014; 32: 3436-3448.
24. De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
25. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-1197.
26. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61: 1079-1092.
27. Kiess A, Minn I, Chen Y, Hobbs R, Sgouros G, Mease RC et al. Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen. J Nucl Med 2015; 56: 1401-1407.
28. Tagawa ST, Akhtar NH, Nikolopoulou A, Vallabhajosula S, Osborne J, Beltran H et al. Phase I trial of fractionated-dose 177Lutetium radiolabeled anti-prostatespecific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer (CRPC). Conference: European Cancer Congress, ECC 2013, Amsterdam, Netherlands. Eur J Cancer 2013; 49: S701-S702.
29. Tagawa ST, Whang YE, Kaur G, Vallabhajosula S, Christos PJ, Nikolopoulou A et al. Phase I trial of docetaxel/prednisone plus fractionated dose radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody 177Lu- J591 in patients with metastatic, castration-resistant prostate cancer (mCRPC). Conference: Annual Meeting of the American Society of Clinical Oncology, ASCO, Chicago, United States, 2014. J Clin Oncol 2014; 32 (Suppl 1): 15.
30. Lutje S, Heskamp S, Cornelissen AS, Poeppel TD, van den Broek SA, Rosenbaum-Krumme S et al. PSMA ligands for radionuclide imaging and therapy of prostate cancer: clinical status. Theranostics 2015; 5: 1388-1401.
31. De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised openlabel trial. Lancet 2010; 376: 1147-1154.
32. Scher HI, Morris MJ, Basch E, Heller G. End points and outcomes in castration resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol 2011; 29: 3695-3704.
33. Evans-Axelsson S, Timmermand O, Bjartell A, Strand SE, Elgqvist J. Radioimmunotherapy for prostate cancer: current status and future possibilities. Semin Nucl Med 2016; 46: 165-179.
34. Wright GL Jr, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996; 48: 326-334.
35. Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010; 11: 1066-1073.
36. Spratt DE, Evans MJ, Davis BJ, Doran MG, Lee MX, Shah N et al. Androgen receptor upregulation mediates radioresistance after ionizing radiation. Cancer Res 2015; 75: 4688-4696.
37. Tosoian JJ, Gorin MA, Rowe SP, Andreas D, Szabo Z, Pienta KJ et al. Correlation of PSMA-targeted 18F-DCFPyL PET/CT findings with immunohistochemical and genomic data in a patient with metastatic neuroendocrine prostate cancer. Clin Genitourin Cancer 2017; 15: e65-e68.